{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:11:21Z","timestamp":1760109081414,"version":"build-2065373602"},"reference-count":20,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"PIUNA 2020 program of the University of Navarra","award":["15058203"],"award-info":[{"award-number":["15058203"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Essential thrombocythemia (ET) is a blood cancer caused by mutations in JAK2 and CALR. It is widely recognized that both mutations lead to the constitutive activation of JAK2\/STAT signaling, although other JAK\/STAT-independent pathogenic mechanisms triggered by these alterations have also been described in ET. In an attempt to study JAK2\/STAT-independent mechanisms derived from CALR mutations, our research group created a C. elegans model with patient-like mutations in calreticulin that lacks JAK counterparts. The introduction of patient-like mutations in the calreticulin of C. elegans leads to an increase in the transcriptional expression of nhr-2, independently of JAK2\/STAT activation. In the present study, we aim to verify if this mechanism is conserved in patients with ET harboring CALR mutations. To do so, we evaluated the expression of potential orthologs of nhr-2 in human cell lines of interest for the study, as well as in bone marrow (BM) or peripheral blood (PB) mononuclear cells from patients with CALR or JAK2 mutations. The results revealed that this mechanism is conserved in CALR-mutated ET patients, since CALR, but not JAK2 mutations, were associated with an overexpression of RXRA in patients with ET. The use of drugs targeting the activation or blockade of this target in the analyzed cell lines did not result in changes in cell viability. However, RXRA might be relevant in the disease, pointing to the need for future research testing retinoids and other drugs targeting RXR\u03b1 for the treatment of ET patients.<\/jats:p>","DOI":"10.3390\/cancers16081511","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T04:21:59Z","timestamp":1713241319000},"page":"1511","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CALR but Not JAK2 Mutations Are Associated with an Overexpression of Retinoid X Receptor Alpha in Essential Thrombocythemia"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1061-7744","authenticated-orcid":false,"given":"Ana","family":"Guijarro-Hern\u00e1ndez","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Genetics, School of Sciences, University of Navarra, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Hurtado","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Genetics, School of Sciences, University of Navarra, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0667-1959","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"Larr\u00e1yoz","sequence":"additional","affiliation":[{"name":"CIMA LAB Diagnostics, Department of Biochemistry and Genetics, School of Sciences, University of Navarra, 31009 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0374-3008","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"Calasanz","sequence":"additional","affiliation":[{"name":"CIMA LAB Diagnostics, Department of Biochemistry and Genetics, School of Sciences, University of Navarra, 31009 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7416-3679","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"Vizmanos","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Genetics, School of Sciences, University of Navarra, 31008 Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Guijarro-Hern\u00e1ndez, A., and Vizmanos, J.L. (2021). A broad overview of signaling in Ph-negative classic myeloproliferative neoplasms. Cancers, 13.","DOI":"10.3390\/cancers13050984"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Guijarro-Hern\u00e1ndez, A., Eder-Azanza, L., Hurtado, C., Navarro-Herrera, D., Ezcurra, B., Novo, F.J., Cabello, J., and Vizmanos, J.L. (2023). Transcriptomic analysis reveals JAK2\/MPL-independent effects of calreticulin mutations in a C. elegans model. Cells, 12.","DOI":"10.3390\/cells12010186"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/sj.leu.2404081","article-title":"JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders","volume":"20","author":"Quentmeier","year":"2006","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/sj.leu.2401608","article-title":"Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles","volume":"14","author":"Uozumi","year":"2000","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/leu.2014.285","article-title":"MARIMO cells harbor a CALR mutation but are not dependent on JAK2\/STAT5 signaling","volume":"29","author":"Kollmann","year":"2015","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0165-4608(97)00017-4","article-title":"A novel myeloid cell line, Marimo, derived from therapy-related acute myeloid leukemia during treatment of essential thrombocythemia: Consistent chromosomal abnormalities and temporary C-MYC gene amplification","volume":"100","author":"Yoshida","year":"1998","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood.V45.3.321.321","article-title":"Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome","volume":"45","author":"Lozzio","year":"1975","journal-title":"Blood"},{"key":"ref_9","first-page":"794","article-title":"Signaling cross-talk between peroxisome proliferator-activated receptor\/retinoid X receptor and estrogen receptor through estrogen response elements","volume":"9","author":"Keller","year":"1995","journal-title":"Mol. Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/bj3530193","article-title":"Dual DNA-binding specificity of peroxisome-proliferator-activated receptor gamma controlled by heterodimer formation with retinoid X receptor alpha","volume":"353","author":"Okuno","year":"2001","journal-title":"Biochem. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"E103","DOI":"10.1002\/ajh.23735","article-title":"A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML","volume":"89","author":"Welch","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_12","first-page":"417","article-title":"RXRA DT448\/9PP generates a dominant active variant capable of inducing maturation in acute myeloid leukemia cells","volume":"107","author":"Ferris","year":"2022","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e1818","DOI":"10.1002\/mgg3.1818","article-title":"Alteration of PPAR-GAMMA (PPARG; PPAR\u03b3) and PTEN gene expression in acute myeloid leukemia patients and the promising anticancer effects of PPAR\u03b3 stimulation using pioglitazone on AML cells","volume":"9","author":"Esmaeili","year":"2021","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10132","DOI":"10.1073\/pnas.97.18.10132","article-title":"Retinoid-related orphan receptor gamma (RORgamma) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis","volume":"97","author":"Kurebayashi","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.17219\/acem\/32934","article-title":"Pro-apoptotic activity of ruxolitinib alone and in combination with hydroxyurea, busulphan, and PI3K\/mTOR Inhibitors in JAK2-positive human cell lines","volume":"24","author":"Smolewski","year":"2015","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41375-018-0234-6","article-title":"Mutant NRAS Q61K is responsible for MAPK pathway activation in the MARIMO cell line and renders these cells independent of the CALR-MPL-JAK2-STAT5 pathway","volume":"32","author":"Han","year":"2018","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000518921","article-title":"The synergistic inhibitory effect of combining MK-2206 and AZD 6244 in MARIMO cells harboring a calreticulin gene mutation","volume":"66","author":"Wang","year":"2021","journal-title":"Chemotherapy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood.2022016832","article-title":"Retinoid X receptor promotes hematopoietic stem cell fitness and quiescence and preserves hematopoietic homeostasis","volume":"141","author":"Porcuna","year":"2023","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1187066","DOI":"10.3389\/fphar.2023.1187066","article-title":"Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo","volume":"14","author":"Rajamani","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3324\/haematol.2021.279152","article-title":"An exciting RXRA mutant revives interest in retinoids for acute myeloid leukemia","volume":"107","author":"Qiu","year":"2021","journal-title":"Haematologica"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1511\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:28:31Z","timestamp":1760106511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["cancers16081511"],"URL":"https:\/\/doi.org\/10.3390\/cancers16081511","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2024,4,16]]}}}